# PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Source: https://onco.cc/trials/nct04683315/  
OnCo record `nct04683315` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Medical College of Wisconsin, now recruiting.

## Summary

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples is a phase 2, interventional study registered as NCT04683315 by Medical College of Wisconsin, with a registry enrolment figure of 84 participants, started 2021-04-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: mFOLFIRINOX Treatment Regimen; Gemcitabine/Nab-paclitaxel Treatment Regimen. Conditions listed: Pancreatic Cancer. Primary outcome: Subjects who receive PurIST classification-directed therapy.. Pancreatic eligibility wording from the registry: "Have suspicion of pancreas adenocarcinoma and plan for endoscopic biopsy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PANCREAS
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04683315
- Phase: 2
- Setting: PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
- Sponsor: Medical College of Wisconsin
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT04683315: https://clinicaltrials.gov/study/NCT04683315

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04683315.json